ARLZ


Aralez Pharmaceuticals (ARLZ) Stock Runs Downhill; Here’s Why

Aralez Pharmaceuticals’ (NASDAQ:ARLZ) share price fell 60% today, leaving the Street at odds over when it will hit a bottom. The reason?

Aralez Pharmaceuticals Inc (ARLZ) Scores a Win in Patent Dispute

Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ) announced that the United States District Court for the District of New Jersey upheld the validity of two patents …

Aralez Pharmaceuticals Inc (ARLZ) Shares on the Rise as CEO Shows Confidence

Aralez Pharmaceuticals Inc (NASDAQ:ARLZ) investors have a smile on their faces following the news that CEO Adrian Adams acquired an additional 500,000 shares …

Company Update (NASDAQ:ARLZ): Aralez Pharmaceuticals Inc Submits Marketing Authorization Application to the European Medicines Agency for PA10040

Aralez Pharmaceuticals Inc (NASDAQ:ARLZ) announced that it has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for its investigational …

Stock Update (NASDAQ:ARLZ): Aralez Pharmaceuticals Inc Announces Commercial Launch of BLEXTEN in Canada for the Treatment of Seasonal Allergic Rhinitis

Aralez Pharmaceuticals Inc (NASDAQ:ARLZ) announced the commercial launch of BLEXTEN (Bilastine 20 mg oral tablet) for the treatment of the symptoms of Seasonal …

Company Update (NASDAQ:ARLZ): Aralez Pharmaceuticals Inc Provides Update on PBM Formulary Status for Yosprala

Aralez Pharmaceuticals Inc (NASDAQ:ARLZ) announced that it has entered into a rebate agreement with CaremarkPCS Health (also known as CVS Caremark), which secures …

Stock Update (NASDAQ:ARLZ): Aralez Pharmaceuticals Inc Provides New Data For YOSPRALA

Aralez Pharmaceuticals Inc (NASDAQ:ARLZ) announced new data for YOSPRALA™, a recently FDA-approved prescription fixed-dose combination of aspirin, an anti-platelet agent, and omeprazole, a …

Company Update (NASDAQ:ARLZ): Aralez Pharmaceuticals Inc Reports Third Quarter 2016 Financial Results

Aralez Pharmaceuticals Inc (NASDAQ:ARLZ) announced financial results for the third quarter ended September 30, 2016. The Company also highlighted certain corporate and commercial updates.

Company Update (NASDAQ:ARLZ): Aralez Pharmaceuticals Inc Completes Acquisition Of Toprol-XL And Its Authorized Generic From AstraZeneca

Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ) announced that its subsidiary, Aralez Pharmaceuticals Trading DAC (Aralez Ireland), has completed its acquisition of the U.

Chardan Reiterates Buy on Aralez Pharmaceuticals Inc (ARLZ) Following Acquisition of U.S. Rights for Toprol-XL

In a research note published Tuesday, Chardan analyst Keay Nakae reiterated a Buy rating on shares of Aralez Pharmaceuticals Inc (NASDAQ:ARLZ) with a price target …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts